In ADU-S100 + anti-ISG15 treated tumors, we observed an increase in the frequency of central memory CD4+ and CD8+ T cells in addition to an increase in effector CD4+ T cell content vs. ADU-S100 treatment alone, suggestive of enhanced anti-tumor T cell activity in situ. This evidence concerns the gene CD8A and neoplasm.